Patents Assigned to Allergan, Inc.
  • Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia
    Patent number: 11077053
    Abstract: Methods of using the alpha-2-adrenergic receptor agonist of Formula I: for improving vision such as in the treatment of ocular conditions such as presbyopia, poor night vision, visual glare, visual starbursts, visual halos, and some forms of myopia (e.g. night myopia) are described.
    Type: Grant
    Filed: November 17, 2020
    Date of Patent: August 3, 2021
    Assignee: ALLERGAN, INC.
    Inventors: Mohammed Dibas, Daniel W. Gil, Wayne Chen, Miguel Alcantara
  • High viscosity macromolecular compositions for treating ocular conditions
    Patent number: 11078262
    Abstract: Anti-angiogenesis compositions, and methods of using such compositions, useful for injection into the vitreous of human eyes are provided. Such compositions include MAAC solutions or particles present in a therapeutically effective amount, a viscosity-inducing component, and an aqueous carrier component. The compositions have viscosities at about 25° C. of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity at 25° C. is in the range of from about 80,000 cps to about 300,000 cps.
    Type: Grant
    Filed: April 30, 2007
    Date of Patent: August 3, 2021
    Assignee: ALLERGAN, INC.
    Inventors: Patrick M. Hughes, Gerald W. DeVries, Robert T. Lyons, John T. Trogden, Scott M. Whitcup
  • Microneedle array with active ingredient
    Patent number: 11065428
    Abstract: Microneedle arrays for introducing an active ingredient through a skin surface of a subject can include a base layer, a plurality of microneedles projecting from the base layer, and an active ingredient. Each of the microneedles comprises an elongate body having a proximal portion and a distal portion, in which the proximal portion is attached to the base layer. Each of the microneedles comprises at least one dissolvable polymer. The active ingredient is incorporated in the elongate body, and the active ingredient is present only in the distal portion and at least internally in the distal portion.
    Type: Grant
    Filed: February 16, 2018
    Date of Patent: July 20, 2021
    Assignee: Allergan, Inc.
    Inventors: Futian Liu, Xiaojie Yu, Lance E. Steward, Guang Wei Lu, Patrick M. Hughes, Sheshadri Neervannan
  • Heavy chain only antibodies to ANG-2
    Patent number: 11046756
    Abstract: Disclosed herein are monospecific HCAb antibodies with antigen-binding specificity to ANG-2 and bispecific antibodies with antigen-binding specificities to ANG-2 and VEGF or PDGF.
    Type: Grant
    Filed: April 16, 2019
    Date of Patent: June 29, 2021
    Assignee: ALLERGAN, INC.
    Inventors: Yanbin Liang, Daniel W. Gil
  • Sulfur derivatives as chemokine receptor modulators
    Patent number: 11046644
    Abstract: The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: June 29, 2021
    Assignee: ALLERGAN, INC.
    Inventors: Haiqing Yuan, Richard L. Beard, Xiaoxia Liu, John E. Donello, Veena Viswanath, Michael E. Garst
  • Artificial tears and therapeutic uses
    Patent number: 11045515
    Abstract: The present invention provides ophthalmic compositions, e.g. artificial tears, suitable for treating dry eye syndrome in a human or other mammal suffering there from, e.g. a dog or cat, which comprise a mixture of castor oil with another oil, e.g. a food oil, e.g. olive oil, sesame oil, corn oil etc.
    Type: Grant
    Filed: October 23, 2017
    Date of Patent: June 29, 2021
    Assignee: ALLERGAN, INC.
    Inventors: Anuradha V. Gore, Robert S. Jordan, Kevin Krock, Chetan Pujara
  • Injection paradigm for administration of botulinum toxins
    Patent number: 11033610
    Abstract: Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin administration for patients suffering headache, particularly chronic migraine.
    Type: Grant
    Filed: September 9, 2019
    Date of Patent: June 15, 2021
    Assignee: Allergan, Inc.
    Inventors: Catherine C. Turkel, Sheena K. Aurora, Mitchell F. Brin
  • Method for stabilizing a toxin
    Patent number: 11033625
    Abstract: Animal protein-free, solid-form Clostridial toxin pharmaceutical compositions comprising a Clostridial toxin active ingredient and at least two excipients.
    Type: Grant
    Filed: October 15, 2020
    Date of Patent: June 15, 2021
    Assignee: Allergan, Inc.
    Inventor: Terrence J. Hunt
  • Heavy chain only antibodies to PDGF
    Patent number: 11028163
    Abstract: Disclosed herein are monospecific HCAb antibodies with antigen-binding specificity to PDGF and bispecific antibodies with antigen-binding specificities to PDGF-2 and VEGF or to PDGF and ANG-2.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: June 8, 2021
    Assignee: ALLERGAN, INC.
    Inventors: Yanbin Liang, Daniel W. Gil
  • Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators
    Patent number: 10993931
    Abstract: The present invention relates to novel amide derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: May 4, 2021
    Assignee: ALLERGAN, INC.
    Inventors: Richard L. Beard, Tien T. Duong, John E. Donello, Veena Viswanath, Michael E. Garst
  • Dissolvable microneedles for skin treatment
    Patent number: 10987503
    Abstract: A skin treatment can include applying a microneedle device to a region of the skin so that microneedles of the device penetrate the stratum corneum. The arrangement of microneedles can have first microneedles with a first length and second microneedles with a second length, different from the first length. The first and second microneedles can be formed from a mixture of a polymeric material and an active agent beneficial to skin. After the device is applied to the skin, the first and second microneedles can be released below the skin surface, followed by dissolution of the first and second microneedles.
    Type: Grant
    Filed: March 30, 2020
    Date of Patent: April 27, 2021
    Assignee: ALLERGAN, INC.
    Inventors: Justin J. Schwab, Michael Augarten, Zachary Dominguez, Ethan Franklin, Edwin J. Kayda, Jason Metzner
  • Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
    Patent number: 10988474
    Abstract: The present invention provides a compound, that is a 1-({halo-2-[(2-hydrocarbyl or substituted hydrocarbyl)oxy]phenyl}methyl)-(fused bicyclic nitrogen heteroaryl) carboxylic acid or an ester or sulfonamide thereof. The compound may be represented by the following formula Wherein R1, R2, R3, R4 A, X, W, Z and Y are as defined in the specification. The compounds may be administered to treat DP, FP, EP1, TP and/or EP4 receptor-mediated diseases or conditions.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: April 27, 2021
    Assignee: ALLERGAN, INC.
    Inventors: William R. Carling, Jose L. Martos, Jussi J. Kangasmetsa, Jenny W. Wang, David F. Woodward
  • Non-protein clostridial toxin compositions
    Patent number: 10973890
    Abstract: Pharmaceutical compositions that stabilize a Clostridial toxin active ingredient are described. The compositions can be liquid or solid compositions, and comprise a surfactant and an antioxidant. In some embodiments, the compositions comprise a surfactant selected from a poloxamer and a polysorbate; an antioxidant selected from methionine, N-acetyl cysteine, ethylenediaminetetraacetic acid and combinations thereof, and, optionally, a tonicity agent and/or a lyoprotector selected from, for example, trehalose, sucrose.
    Type: Grant
    Filed: August 5, 2019
    Date of Patent: April 13, 2021
    Assignee: Allergan, Inc.
    Inventors: Maurice Abiad, Bhas Dani, Evgenyi Shalaev
  • Botulinum neurotoxin for treatment of disorders associated with melanocyte hyperactivity and/or excess melanin
    Patent number: 10912823
    Abstract: Methods for treating melanin-related afflictions of the skin, such as hyperpigmentation, are provided. The methods comprise administering a composition comprising BoNT/DC.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: February 9, 2021
    Assignee: Allergan, Inc.
    Inventors: Birgitte P.S. Jacky, Shiazah Z. Malik, Joanne Wang, Yi Liu, Amy Brideau-Andersen, Lance E. Steward, Linh Q. Le, Edward C. Hsai
  • Androgen composition for treating an ophthalmic condition
    Patent number: 10905696
    Abstract: The disclosure provides compositions for treating an ocular condition. The composition comprises a physiologically effective amount of an androgen, wherein the composition is suitable for topical administration to an eye. The disclosure further provides methods for treating an ocular condition with the disclosed compositions.
    Type: Grant
    Filed: November 28, 2016
    Date of Patent: February 2, 2021
    Assignee: ALLERGAN, INC.
    Inventors: John T. Trogden, Adnan K. Salameh, Chetan P. Pujara, Anuradha V. Gore, Jaya Giyanani
  • Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation
    Patent number: 10905797
    Abstract: Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and optionally including proteins. In one aspect, hyaluronic acid-based compositions described herein include zero-length cross-linked moieties and optionally at least one active agent. The present hyaluronic acid-based compositions have enhanced flow characteristics, hardness, and persistence compared to known hyaluronic acid-based compositions. Methods and processes of preparing such hyaluronic acid-based compositions are also provided.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: February 2, 2021
    Assignee: ALLERGAN, INC.
    Inventors: Karina Heredia Guillen, Ahmet Tezel
  • Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases
    Patent number: 10899780
    Abstract: The present invention relates to a method for treating ocular inflammatory diseases in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2.
    Type: Grant
    Filed: January 22, 2019
    Date of Patent: January 26, 2021
    Assignee: ALLERGAN, INC.
    Inventors: Richard L. Beard, John E. Donello, Veena Viswanath
  • Bioerodible matrix for tissue involvement
    Patent number: 10898607
    Abstract: Disclosed herein are polyurethane polymer matrices with a porosity of from about 20 microns to about 90 microns that are useful in promoting closure and protection of incision sites; supporting the lower pole position of breast implants; and providing a partial or complete covering of breast implants to provide a beneficial interface with host tissue and to reduce the potential for malpositioning or capsular contracture. The disclosed matrices can be seeded with mammalian cells.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: January 26, 2021
    Assignee: ALLERGAN, INC.
    Inventors: Dennis E. Van Epps, Thomas E. Powell
  • Immuno-based retargeted endopeptidase activity assays
    Patent number: 10900967
    Abstract: The present specification discloses a retargeted endopeptidase pharmaceutical wherein the activity has been determined by the methods disclosed.
    Type: Grant
    Filed: July 8, 2019
    Date of Patent: January 26, 2021
    Assignee: Allergan, Inc.
    Inventors: Joanne Wang, Hong Zhu, Dianne D. Hodges, Ester Fernandez-Salas
  • Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
    Patent number: 10888598
    Abstract: Provided herein are low salt ophthalmic pharmaceutical composition and methods of use thereof, for example, in the treatment of dry eye syndrome.
    Type: Grant
    Filed: January 23, 2018
    Date of Patent: January 12, 2021
    Assignee: ALLERGAN, INC.
    Inventors: Peter A. Simmons, Joseph G. Vehige